BioSpace News Archive

Inspired by a color changing mechanism found in cephalopods, like squid, cuttlefish and octopus, researchers at the University of New Hampshire have conceived a design for a unique sequential cell-opening mechanism that has many potential applications from drug delivery to color altering camouflage materials.

Auspherix Limited, the anti-infectives company meeting the urgent need for new antibiotics by developing a novel class of antibacterials, today announced that it is presenting proprietary bioanalytical methods to characterise the in vivo pharmacokinetic profile and PK/PD relationship of its compounds, following systemic dosing in rodents.

xCell today reports its revenues for the third quarter of 2017 and its cash position as of September 30, 2017.

Biofrontera today provided an update on the commercialization progress for its combination topical prescription drug Ameluz and medical device BF-RhodoLED for the photodynamic therapy (PDT) of actinic keratosis, a skin cancer precursor, in the United States.

Janssen Biotech announced today that the FDA has approved SIMPONI ARIA (golimumab), the only fully-human anti-TNF-alpha therapy administered via a 30-minute infusion, for the treatment of adults with active psoriatic arthritis or active ankylosing spondylitis (AS).

Spero plans for a rapid development approach with SPR994.

M3 Biotechnology is a clinical stage company with a novel platform of disease-modifying regenerative therapies particularly relevant to neurodegenerative diseases, with a focus on Alzheimer’s. M3’s lead asset, NDX-1017, modifies growth factor systems and is advanced as a first-in-class, disease-modifying treatment with the potential to restore lost connections between brain cells, turning degeneration into regeneration.

The Orphan Drug designation allows RedHill to benefit from various development incentives to develop MESUPRON for this indication.

The agreement calls for (i) upfront technology license fees and stocking orders of $5 million; (ii) minimum royalty payments from the sale of SonaStar products.

Chris Linthwaite, President and CEO, and Vikram Jog, Chief Financial Officer, will host a conference call at 2:00 p.m. PT (5:00 p.m. ET) on November 2, 2017.